Drug intelligence / Profile preview

rhRIG + vaccine

Development stage: Unknown
Lead developer: Molecular Targeting Technologies
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
Administration: Wound Infiltration, Intramuscular

Overview

rhRIG + vaccine is a combination therapy for post-exposure prophylaxis against rabies. It consists of recombinant human anti-rabies monoclonal antibody (rhRIG, also known as Ormutivimab) administered in conjunction with rabies vaccine. The rhRIG component provides immediate passive immunity at the wound site, offering protection during the window period before the rabies vaccine establishes active immunity. This combination approach is designed to prevent the onset of rabies following potential exposure to the virus.

Other names: recombinant human anti-rabies monoclonal antibody NM57 injection + rabies vaccine

Targets

RABV-G (Rabies virus glycoprotein)

Beyond the preview

Go deeper on rhRIG + vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rhRIG + vaccine.

Explore the full profile